EP1322326A4 - Vaccins diriges vers le systeme immunitaire inne - Google Patents

Vaccins diriges vers le systeme immunitaire inne

Info

Publication number
EP1322326A4
EP1322326A4 EP01965846A EP01965846A EP1322326A4 EP 1322326 A4 EP1322326 A4 EP 1322326A4 EP 01965846 A EP01965846 A EP 01965846A EP 01965846 A EP01965846 A EP 01965846A EP 1322326 A4 EP1322326 A4 EP 1322326A4
Authority
EP
European Patent Office
Prior art keywords
immune system
innate immune
directed vaccines
vaccines
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01965846A
Other languages
German (de)
English (en)
Other versions
EP1322326A1 (fr
Inventor
Ruslan M Medzhitov Ph D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/752,832 external-priority patent/US20020061312A1/en
Application filed by Yale University filed Critical Yale University
Publication of EP1322326A1 publication Critical patent/EP1322326A1/fr
Publication of EP1322326A4 publication Critical patent/EP1322326A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP01965846A 2000-07-31 2001-07-31 Vaccins diriges vers le systeme immunitaire inne Ceased EP1322326A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22204200P 2000-07-31 2000-07-31
US222042P 2000-07-31
US25832900P 2000-12-28 2000-12-28
US258329P 2000-12-28
US752832 2001-01-03
US09/752,832 US20020061312A1 (en) 2000-07-31 2001-01-03 Innate immune system-directed vaccines
US28260401P 2001-04-09 2001-04-09
US282604P 2001-04-09
PCT/US2001/024228 WO2002009748A1 (fr) 2000-07-31 2001-07-31 Vaccins diriges vers le systeme immunitaire inne

Publications (2)

Publication Number Publication Date
EP1322326A1 EP1322326A1 (fr) 2003-07-02
EP1322326A4 true EP1322326A4 (fr) 2005-08-17

Family

ID=27499260

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01965846A Ceased EP1322326A4 (fr) 2000-07-31 2001-07-31 Vaccins diriges vers le systeme immunitaire inne

Country Status (5)

Country Link
EP (1) EP1322326A4 (fr)
CN (1) CN1549726A (fr)
AU (2) AU2001286405B2 (fr)
CA (1) CA2418036A1 (fr)
WO (1) WO2002009748A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (fr) 2001-04-20 2014-11-19 The Institute for Systems Biology Ligands de recepteur de type 5 et procedes d'utilisation
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005042017A1 (fr) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions et procedes pour activer une immunite innee et une immunite aux allergies
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
TWI404537B (zh) * 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1991264B1 (fr) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions comprenant de l'hémagglutinine, leurs procédés de fabrication et leurs procédés d'utilisation
WO2009068630A1 (fr) 2007-11-27 2009-06-04 Ablynx N.V. Constructions d'immunoglobuline
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
EP2632434A1 (fr) 2010-10-26 2013-09-04 AC Immune S.A. Préparation d'un produit de recombinaison antigénique
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961702B (zh) * 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
RU2679889C2 (ru) * 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
EP3302511A1 (fr) * 2015-06-02 2018-04-11 De Staat der Nederlanden, vert. door de Minister van VWS Présentation en surface d'antigènes sur des vésicules de membrane externes à gram négatif
EP3362168A1 (fr) * 2015-10-14 2018-08-22 Novozymes A/S Nettoyage de membranes de filtration d'eau
US11226340B2 (en) 2016-04-26 2022-01-18 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue
WO2018009916A1 (fr) * 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Conjugués d'adjuvant d'anticorps
CN112940135A (zh) * 2019-12-11 2021-06-11 四川农业大学 融合蛋白、其氨基酸序列、编码核苷酸序列、制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (fr) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1996032963A1 (fr) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
WO1996040290A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Compositions renfermant une association immunologique, et procedes correspondants
WO1999039735A1 (fr) * 1998-02-06 1999-08-12 Research Development Foundation Vaccin vivant contre le virus de l'immunodeficience humaine
WO1999047168A2 (fr) * 1998-03-16 1999-09-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction et stimulation de la reponse immunitaire a des antigenes independants des lymphocytes t de type 2 conjugues a des fractions lipidiques ou contenant un lipide
WO1999049892A2 (fr) * 1998-03-27 1999-10-07 Pierre Fabre Medicament Utilisation de conjugues p40 actifs par voie nasale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926919T2 (de) * 1988-09-26 1997-01-30 Biotech Australia Pty Ltd Vakzin gegen Nematoden
DE69012318T2 (de) * 1989-03-09 1995-03-09 Praxis Biolog Inc Impfstoffe gegen hämophilus influenzae.
JPH05501656A (ja) * 1990-08-08 1993-04-02 バイオメイ　バイオテクニック　プロダクションズ　ウント　ヘンデルスゲゼルシャフト　エム．　ベー．　ハー． ハンノキの花粉のアレルゲンおよびその用途
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE19529302A1 (de) * 1995-08-09 1997-02-13 Siemens Ag Vorrichtung zur Kompensation von Oberschwingungsströmen einer aus mehreren Leitern bestehenden Übertragungsstrecke

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (fr) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1996032963A1 (fr) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
WO1996040290A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Compositions renfermant une association immunologique, et procedes correspondants
WO1999039735A1 (fr) * 1998-02-06 1999-08-12 Research Development Foundation Vaccin vivant contre le virus de l'immunodeficience humaine
WO1999047168A2 (fr) * 1998-03-16 1999-09-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction et stimulation de la reponse immunitaire a des antigenes independants des lymphocytes t de type 2 conjugues a des fractions lipidiques ou contenant un lipide
WO1999049892A2 (fr) * 1998-03-27 1999-10-07 Pierre Fabre Medicament Utilisation de conjugues p40 actifs par voie nasale

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BECKER R S ET AL: "CO-ADMINISTRATION OF SOLUBLE AND PARTICULATE FORMS OF CONJUGATE, OSPA, AND HA ANTIGENS SYNERGISTICALLY ENHANCE IMMUNE RESPONSES", VACCINES MODERN APPROACHES TO NEW VACCINES, NEW YORK, NY, US, January 1993 (1993-01-01), pages 347 - 351, XP000574928 *
EAVES-PYLES ET AL, THE JOURNAL OF IMMUNOLOGY, vol. 166, 15 January 2001 (2001-01-15), pages 1248 - 1260, XP002210841 *
ERDILE L F ET AL: "OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 9, June 1997 (1997-06-01), pages 988 - 995, XP004115364, ISSN: 0264-410X *
FEARON D T ET AL: "THE INSTRUCTIVE ROLE OF INNATE IMMUNITY IN THE ACQUIRED IMMUNE RESPONSE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 272, no. 5258, 5 April 1996 (1996-04-05), pages 50 - 54, XP009039507, ISSN: 0036-8075 *
FRANCISCO J A ET AL: "TRANSPORT AND ANCHORING OF BETA-LACTAMASE TO THE EXTERNAL SURFACE OF ESCHERICHIA COLI", BIOCHEMISTRY, CONSULTANTS BUREAU, NEW YORK, NY, US, vol. 89, 1 April 1992 (1992-04-01), pages 2713 - 2717, XP001203586, ISSN: 0006-2979 *
GEWIRTZ ET AL, THE JOURNAL OF CLINICAL INVESTIGATION, vol. 107, January 2001 (2001-01-01), pages 99 - 109, XP002210842 *
HAYASHI ET AL, NATURE, vol. 410, 26 April 2001 (2001-04-26), pages 1099 - 1103, XP002210843 *
MCEWEN ET AL: "Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagelin leads to partial protection in mice", VACCINE, vol. 10, no. 6, 1992, pages 405 - 411 *
MEDZHITOV R ET AL: "Innate immunity: impact on the adaptive immune response", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 9, no. 1, February 1997 (1997-02-01), pages 4 - 9, XP004327225, ISSN: 0952-7915 *
NEWTON S M C ET AL: "IMMUNE RESPONSE TO CHOLERA TOXIN EPITOPE INSERTED IN SALMONELLA FLAGELLIN", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 244, no. 4900, 1989, pages 70 - 72, XP001094029, ISSN: 0036-8075 *
RAULY I ET AL: "Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 11, November 1999 (1999-11-01), pages 5547 - 5551, XP002138526, ISSN: 0019-9567 *
SCHREUDER M P ET AL: "Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 5, April 1996 (1996-04-01), pages 383 - 388, XP004057292, ISSN: 0264-410X *
See also references of WO0209748A1 *
SMITH K D ET AL: "Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 4, no. 12, 1 December 2003 (2003-12-01), pages 1247 - 1253, XP002999619, ISSN: 1529-2908, DOI: 10.1038/NI1011 *
STOCKER ET AL, INTERN. REV. IMMUNOL., vol. 11, 1994, pages 167 - 178, XP000612018 *
UEDA M ET AL: "Genetic immobilization of proteins on the yeast cell surface", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 18, no. 2, April 2000 (2000-04-01), pages 121 - 140, XP004205315, ISSN: 0734-9750 *
VAN DE VERG L L ET AL: "Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 64, no. 12, December 1996 (1996-12-01), pages 5263 - 5268, XP002088714, ISSN: 0019-9567 *
WYANT ET AL, INFECTION AND IMMUNITY, vol. 67, July 1999 (1999-07-01), pages 3619 - 3624, XP002415285 *
WYANT ET AL, INFECTION AND IMMUNITY, vol. 67, March 1999 (1999-03-01), pages 1338 - 1346 *

Also Published As

Publication number Publication date
WO2002009748A9 (fr) 2003-04-03
CN1549726A (zh) 2004-11-24
CA2418036A1 (fr) 2002-02-07
AU2001286405B2 (en) 2007-05-10
AU8640501A (en) 2002-02-13
WO2002009748A1 (fr) 2002-02-07
EP1322326A1 (fr) 2003-07-02

Similar Documents

Publication Publication Date Title
AU8640501A (en) Innate immune system-directed vaccines
IL155282A0 (en) Vaccines
GB0020953D0 (en) Vaccine
HUP0301092A3 (en) Vaccine
IL155072A0 (en) Vaccine
HUP0202885A3 (en) Vaccines
AU2002336760A8 (en) Mutable vaccines
PL370359A1 (en) Vaccines
GB0024200D0 (en) Component vaccine
AU1591402A (en) Vaccine
GB0014288D0 (en) Vaccine
AU2002361682A8 (en) Innate immune system-directed vaccines
HUP0300354A3 (en) Hiv immune adjuvant therapy
GB9901254D0 (en) Vaccines
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
GB0025694D0 (en) Vaccine
GB0003082D0 (en) Vaccine
GB0004533D0 (en) Vaccines
GB0014437D0 (en) Immune response stimulation
GB0015722D0 (en) Vaccine
GB0006693D0 (en) Vaccine
GB0015935D0 (en) Vaccine
GB0006281D0 (en) Vaccines
GB0014280D0 (en) Vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030227

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050629

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20131024

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055393

Country of ref document: HK